Skip to the content
Please enable JavaScript in your browser to complete this form.
Hybrid expert panel meeting Renal cell carcinoma: Updates on treatment and management
Specialty
*
Oncology
Urology
Region
*
Hong Kong
Taiwan
Affiliation
*
HA
Private practice
1. What factors currently drive your treatment choices in RCC?
(Please rank according to the importance of treatment decision making)
IMDC risk
*
[Please select]
1st
2nd
3rd
4th
5th
Histology
*
[Please select]
2nd
3rd
4th
5th
Histology
*
[Please select]
1st
3rd
4th
5th
Histology
*
[Please select]
1st
2nd
4th
5th
Histology
*
[Please select]
1st
2nd
3rd
5th
Histology
*
[Please select]
1st
2nd
3rd
4th
Access and reimbursement(1-2)
*
[Please select]
3rd
4th
5th
Access and reimbursement(1-3)
*
[Please select]
2nd
4th
5th
Access and reimbursement(1-4)
*
[Please select]
2nd
3rd
5th
Access and reimbursement(1-5)
*
[Please select]
2nd
3rd
4th
Access and reimbursement(2-3)
*
[Please select]
1st
4th
5th
Access and reimbursement(2-4)
*
[Please select]
1st
3rd
5th
Access and reimbursement(2-5)
*
[Please select]
1st
3rd
4th
Access and reimbursement(3-4)
*
[Please select]
1st
2nd
5th
Access and reimbursement(3-5)
*
[Please select]
1st
2nd
4th
Access and reimbursement(4-5)
*
[Please select]
1st
2nd
3rd
Comorbidities
1st
2nd
3rd
4th
5th
1st
Item #1 1st
2nd
Item #1 2nd
3rd
Item #1 3rd
4th
Item #1 4th
5th
Item #1 5th
Tumour burden/aggressiveness of disease
1st
2nd
3rd
4th
5th
1st
Item #1 1st
2nd
Item #1 2nd
3rd
Item #1 3rd
4th
Item #1 4th
5th
Item #1 5th
2. What proportion of your RCC patients receive the below regimens as first-line systemic therapy?
(Please input a numerical % value)
Pazopanib or sunitinib
Nivolumab + ipilimumab
Pembrolizumab + axitinib
Cabozantinib + nivolumab
Pembrolizumab + lenvatinib
Cabozantinib
3. What proportion of your RCC patients are eligible for second-line systemic therapy?
(Please input a numerical % value)
3.
4. What proportion of your patients with RCC receive the below therapies in the second-line setting?
(Please input a numerical % value)
Cabozantinib
Axitinib
Lenvatinib + everolimus
Nivolumab
5. What proportion of your RCC patients are eligible for third-line systemic therapy?
(Please input a numerical % value)
5.
6. Which adverse events of cabozantinib do you find most challenging?
(You may select more than one)
6. Which adverse events of cabozantinib do you find most challenging? (You may select more than one)
Hand-foot skin reaction
Hypertension
Diarrhoea
Liver enzyme derangement
Stomatitis
Mucosal inflammation
Fatigue
Other
Please specify :
Submit